Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Triple Negative Breast Neoplasms × darolutamide × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 4 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Male Urogenital Diseases 1 Genital Diseases, Male 1 Carcinoma, Non-Small-Cell Lung 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms 1

Interventions

pembrolizumab 31 Nivolumab 14 Paclitaxel 13 Carboplatin 13 Cyclophosphamide 12 sacituzumab govitecan 8 Cisplatin 8 Capecitabine 7 130-nm albumin-bound paclitaxel 7 Gemcitabine 6 fludarabine 5 durvalumab 5 avelumab 5 atezolizumab 5 Magnetic Resonance Spectroscopy 5 Biopsy 5 camrelizumab 4 Specimen Handling 4 Ipilimumab 4 Interleukin-2 4 Injections 4 Immune Checkpoint Inhibitors 4 Docetaxel 4 toripalimab 3 talazoparib 3 Leucovorin 3 Immunoglobulin G 3 Everolimus 3 Clinical Trials, Phase II as Topic 3 Bevacizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05272709 2024-05-13

CURATE

Cancer Research UK

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡